Thoracic 2017: SBRT Offers Curative Option for Patients With Lung Cancer Aged 80 and Older
Patients in their 80s and 90s who have early-stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to research presented by Cassidy et al at the 2017 Multidisciplinary Thoracic Cancers Symposium (Abstract 111). The advanced form of radiation therapy (RT) was well-tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.
While the primary treatment for early-stage lung cancer is surgical removal of the tumor, some patients may not be able to tolerate surgery due to health status, advanced age, or other factors. For these patients, the best curative option is SBRT, a specialized type of external beam RT that uses advanced imaging techniques to deliver extremely targeted radiation to a tumor. This high degree of precision makes SBRT particularly effective at sparing surrounding healthy tissue, which is important for tumor sites near essential organs, such as the heart and lungs. Patients complete SBRT treatment in 3 to 5 days, compared with several weeks for conventional RT.
“While multiple studies and trials have established the effectiveness of SBRT for inoperable early-stage lung cancer, one of the common reasons for not giving radiation in older patients is concern about tolerating the treatment and potential side effects,” said Richard J. Cassidy III, MD, lead author of the study and a resident in radiation oncology at Emory University’s Winship Cancer Institute. “The low rates of side effects from SBRT for this elderly population in our study indicate that these concerns should not prevent physicians from considering definitive treatment for their inoperable octogenarian and nonagenarian patients with early-stage lung cancer.”
Study Findings
Findings are based on a retrospective analysis of 58 consecutive patients who received definitive lung SBRT across four academic sites within Emory between 2010 and 2015. All patients were age 80 or older at the time of their diagnosis, with a median age of 84.9 years. Forty percent of the tumors were adenocarcinomas, while 29% were squamous cell carcinomas and 31% did not have a biopsy. Fifty percent of patients who did not have a biopsy had a previous history of lung cancer. Researchers used logistic regression and proportional hazard testing to determine the association of patient, tumor, and treatment characteristics to compare rates of survival, recurrence, and progression and assess the influence of patient and disease characteristics. Recursive partitioning analysis (RPA) was conducted to determine which patients were most likely to benefit from therapy.
At 2 years following definitive SBRT for lung cancer among elderly patients, survival rates were 73% for cancer-specific survival and 57% for overall survival. Cancer-specific survival rates were higher for patients who were not active smokers but lower for patients who were older or had a previous lung cancer diagnosis (smoking hazard ratio [HR] = 0.14, P = .03; age HR = 1.19, P = .04; cancer HR = 7.75, P = .01). Overall survival rates were higher for patients with higher Karnofsky performance status (KPS), which measures a patient’s functional ability to perform ordinary tasks, such as work and self-care (HR = 0.91, P < .01). Researchers determined that this metric should be considered when offering SBRT in this elderly population, with certain performance status criterion (ie, KPS ≥ 75) associated with significantly improved outcomes.
Two-year estimates of local control and regional control were 84.5% and 71.7%, respectively. Local failure was more common among patients with adenocarcinomas (HR = 6.36, P = .01) and less common for patients with T1 tumors (HR = 0.20, P < .01). Higher KPS scores were associated with lower rates of both local failure (HR = 0.92, P < .01) and regional failure (HR = 0.94, P < .01). In terms of toxicity, just over one-third of patients (34.5%) experienced radiation pneumonitis of any grade, with only two patients experiencing grade ≥ 3 pneumonitis. Pneumonitis was more frequent among patients who were not actively using ace inhibitors (odds ratio [OR] = 3.49, P = .02) and less frequent in smaller tumors (OR = 0.03, P < .01).
“Our study, along with other studies, helps to show that SBRT can effectively and safely add years to the lives of elderly patients who have early-stage lung cancer but cannot undergo an operation for it,” said Dr. Cassidy. “Elderly patients who are otherwise doing well should not have treatment withheld based solely on concerns about side effects and age.”
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
